<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30130984</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>19</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>19</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-7607</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>14</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Expert opinion on drug metabolism &amp; toxicology</Title>                <ISOAbbreviation>Expert Opin Drug Metab Toxicol</ISOAbbreviation>            </Journal>            <ArticleTitle>Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>891-900</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17425255.2018.1514720</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cyclin-dependent kinases (CDKs) 4 and 6 regulate the transition from G0/G1-phase to S-phase of the cell cycle and have been identified as key drivers of proliferation in hormone receptor (HR)-positive breast cancer. The CDK4/6 inhibitor palbociclib in combination with endocrine therapy has been approved for treatment of HR-positive/HER2-negative breast cancer patients. Areas covered: In this article, we provide an update of the data on pharmacodynamics, pharmacokinetics, preclinical, and clinical studies of palbociclib in breast cancer. We performed a search of data on palbociclib in the PubMed and the clinicaltrials.gov databases, in the FDA website and in the ASCO and AACR proceedings. Expert opinion: In order to optimize the clinical outcome of HR-positive breast cancer patients treated with palbociclib, predictive biomarkers allowing patient selection are urgently needed. A recent study suggested that early dynamics of PIK3CA mutations in circulating tumor DNA might be a potential predictive biomarker for CDK4/6 inhibitors. Several clinical trials are ongoing with the aim to explore the activity of combinations of palbociclib with targeted agents and/or immunotherapy in the different subtypes of breast cancer in both metastatic and early phases of the disease. These combinations might allow improving the sensitivity and overcoming mechanisms of resistance.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>De Luca</LastName>                    <ForeName>Antonella</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maiello</LastName>                    <ForeName>Monica R</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>D'Alessio</LastName>                    <ForeName>Amelia</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Frezzetti</LastName>                    <ForeName>Daniela</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gallo</LastName>                    <ForeName>Marianna</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carotenuto</LastName>                    <ForeName>Marianeve</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Normanno</LastName>                    <ForeName>Nicola</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori-IRCCS-&quot;Fondazione G. Pascale&quot; , Naples , Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Expert Opin Drug Metab Toxicol</MedlineTA>            <NlmUniqueID>101228422</NlmUniqueID>            <ISSNLinking>1742-5255</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.22</RegistryNumber>                <NameOfSubstance UI="C495900">CDK4 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.22</RegistryNumber>                <NameOfSubstance UI="C495911">CDK6 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.22</RegistryNumber>                <NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.22</RegistryNumber>                <NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>G9ZF61LE7G</RegistryNumber>                <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CDK4/6 inhibitors</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">cell cycle</Keyword>            <Keyword MajorTopicYN="N">hormone receptor</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30130984</ArticleId>            <ArticleId IdType="doi">10.1080/17425255.2018.1514720</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>